북미의 정맥내 수액 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 영양소별 및 부문별 예측(2026-2033년)

North America Intravenous Solutions Market Summary

The North America intravenous solutions market size was estimated at USD 5.61 billion in 2025 and is projected to reach USD 11.18 billion by 2033, growing at a CAGR of 9.2% from 2026 to 2033. The rising prevalence of chronic diseases, the increasing demand for parenteral nutrition and critical care support, and the presence of advanced healthcare infrastructure, coupled with high surgical volumes across North America.

These factors collectively drive the demand for intravenous solutions across hospitals, intensive care units, and infusion centers. The rising burden of chronic diseases including cancer, chronic kidney disease, and gastrointestinal disorders continues to expand the patient pool requiring long-term intravenous therapy for hydration, drug delivery, and nutritional support. According to the Centers for Disease Control and Prevention published study in 2025, 6 in 10 adults in the U.S. have at least one chronic disease, and 4 in 10 have two or more. This highlights a significant demand for ongoing clinical management. In addition, the American Cancer Society estimates over 2 million new cancer cases annually in the U.S. in 2025, many requiring IV solutions for chemotherapy and supportive care, which drives the need for IV fluid and electrolyte management.

Moreover, the increasing demand for parenteral nutrition and critical care support significantly drives the market, especially in intensive care units (ICUs), neonatal care, and post-surgical settings. A growing number of critically ill and malnourished patients require intravenous nutritional support when oral or enteral feeding is not possible. This is particularly true in cases of severe illness, trauma, premature births, and complex surgical recoveries. Therapies such as total parenteral nutrition (TPN) and peripheral parenteral nutrition (PPN) have become essential in patient management, boosting the demand for IV solutions in acute and critical care environments.

In addition, advanced healthcare infrastructure and high surgical volumes in North America contribute significantly to market growth. The region has a well-established network of hospitals, ambulatory surgical centers, and specialized care facilities that routinely use intravenous therapies for many medical procedures. Surgical interventions, from routine to complex, require consistent administration of IV fluids for perioperative stabilization and post-operative recovery. The strong presence of skilled healthcare professionals and broad access to advanced treatment technologies ensure the continued efficient use of IV solutions across clinical settings.

Furthermore, the increasing demand for intravenous fluids is further driven by rising hospital admissions and critical care needs. The growing burden on healthcare systems, especially in acute and emergency care, has intensified the need for a consistent, reliable supply of IV solutions. For instance, in January 2025, Baxter International Inc. increased allocations of two sodium chloride IV solutions to 100% to improve product availability across the U.S. healthcare system. However, the company reported a 1-2-week distribution lag, with some hospitals experiencing delays of 2-3 weeks due to ongoing supply chain constraints. This shows how rising clinical demand is pushing manufacturers to enhance production capacity and streamline distribution networks to ensure uninterrupted supply.

North America Intravenous Solutions Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the North America intravenous solutions market report based on type, nutrients, end use and regions:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Total Parenteral Nutrition Market (TPN)
• Peripheral Parenteral Nutrition (PPN)
• Nutrients Outlook (Revenue, USD Million, 2021 - 2033)
• Carbohydrates
• Single dose amino acid solution
• Vitamins & Minerals (Salt and electrolyte)
• Parenteral lipid emulsion
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Infusion Centers
• Home Healthcare
• Country Outlook (Revenue, USD Million, 2021 - 2033)
• U.S.
• Canada
• Mexico

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Nutrients
  • 1.2.3. End use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
  • 1.8.2. Volume Price Analysis
  • 1.8.3. Triangulation Analysis
  • 1.8.4. CAGR Growth Assumption and Logics
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Demand for Parenteral Nutrition and Critical Care Support
    • 3.2.1.2. Advanced Healthcare Infrastructure & High Surgical Volume
    • 3.2.1.3. Rising Prevalence of Chronic Diseases
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Stringent Regulatory Requirements
    • 3.2.2.2. Supply Chain Disruptions & High Production Costs
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
  • 3.2.5. Pricing Analysis
  • 3.2.6. Emerging Trends
• 3.3. Business Environment Analysis
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal Landscape

Chapter 4. North America Intravenous Solutions Market: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. Type Market Share Movement Analysis, 2025 & 2033
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Total Parenteral Nutrition Market (TPN)
  • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Peripheral Parenteral Nutrition (PPN)
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. North America Intravenous Solutions Market: Nutrients Estimates & Trend Analysis

• 5.1. Nutrients Segment Dashboard
• 5.2. Nutrients Market Share Movement Analysis, 2025 & 2033
• 5.3. Market Size & Forecasts and Trend Analysis, by Nutrients, 2021 to 2033 (USD Million)
• 5.4. Carbohydrates
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Single dose amino acid solution
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Vitamins & Minerals (Salt and electrolyte)
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Parenteral lipid emulsion
  • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. North America Intravenous Solutions Market: End Use Estimates & Trend Analysis

• 6.1. End use Segment Dashboard
• 6.2. End use Market Share Movement Analysis, 2025 & 2033
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Infusion Centers
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Home Healthcare
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. North America Intravenous Solutions Market: Country Estimates & Trend Analysis

• 7.1. Country Market Dashboard
• 7.2. Country Market: Key Takeaways
• 7.3. U.S.
  • 7.3.1. Key country dynamic
  • 7.3.2. Regulatory framework
  • 7.3.3. Competitive insights
  • 7.3.4. U.S. Intravenous Solutions market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.4. Canada
  • 7.4.1. Key country dynamic
  • 7.4.2. Regulatory framework
  • 7.4.3. Competitive insights
  • 7.4.4. Canada Intravenous Solutions market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Mexico
  • 7.5.1. Key country dynamic
  • 7.5.2. Regulatory framework
  • 7.5.3. Competitive insights
  • 7.5.4. Mexico Intravenous Solutions market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis, 2025
• 8.3. Company Market Share Analysis, 2025 (%)
• 8.4. Company Categorization
• 8.5. Strategy Mapping
• 8.6. Company Profiles/Listing
  • 8.6.1. Baxter
    • 8.6.1.1. Overview
    • 8.6.1.2. Financial performance
    • 8.6.1.3. Product benchmarking
    • 8.6.1.4. Strategic initiatives
  • 8.6.2. Fresenius Kabi AG
    • 8.6.2.1. Overview
    • 8.6.2.2. Financial performance
    • 8.6.2.3. Product benchmarking
    • 8.6.2.4. Strategic initiatives
  • 8.6.3. B. Braun AG
    • 8.6.3.1. Overview
    • 8.6.3.2. Financial performance
    • 8.6.3.3. Product benchmarking
    • 8.6.3.4. Strategic initiatives
  • 8.6.4. ICU Medical, Inc.
    • 8.6.4.1. Overview
    • 8.6.4.2. Financial performance
    • 8.6.4.3. Product benchmarking
    • 8.6.4.4. Strategic initiatives
  • 8.6.5. Pfizer Inc.
    • 8.6.5.1. Overview
    • 8.6.5.2. Financial performance
    • 8.6.5.3. Product benchmarking
    • 8.6.5.4. Strategic initiatives
  • 8.6.6. Otsuka Pharmaceutical Co., Ltd.
    • 8.6.6.1. Overview
    • 8.6.6.2. Financial performance
    • 8.6.6.3. Product benchmarking
    • 8.6.6.4. Strategic initiatives
  • 8.6.7. Grifols, S.A.
    • 8.6.7.1. Overview
    • 8.6.7.2. Financial performance
    • 8.6.7.3. Product benchmarking
    • 8.6.7.4. Strategic initiatives
  • 8.6.8. JW Life Science
    • 8.6.8.1. Overview
    • 8.6.8.2. Financial performance
    • 8.6.8.3. Product benchmarking
    • 8.6.8.4. Strategic initiatives
  • 8.6.9. CSLVifor (formerly Vifor Pharma)
    • 8.6.9.1. Overview
    • 8.6.9.2. Financial performance
    • 8.6.9.3. Product benchmarking
    • 8.6.9.4. Strategic initiatives
  • 8.6.10. BD (Becton, Dickinson and Company)
    • 8.6.10.1. Overview
    • 8.6.10.2. Financial performance
    • 8.6.10.3. Product benchmarking
    • 8.6.10.4. Strategic initiatives
  • 8.6.11. Terumo Corporation
    • 8.6.11.1. Overview
    • 8.6.11.2. Financial performance
    • 8.6.11.3. Product benchmarking
    • 8.6.11.4. Strategic initiatives
  • 8.6.12. Amphastar Pharmaceuticals, Inc.
    • 8.6.12.1. Overview
    • 8.6.12.2. Financial performance
    • 8.6.12.3. Product benchmarking
    • 8.6.12.4. Strategic initiatives